Clinical trials: Malaria
Malaria, Severe Malaria
Monoclonal Antibodies in Children With Severe Anaemia or Severe Malaria to Prevent Malaria After Hospital Discharge
Background and rationale: Hospitalised children with severe anaemia remain at high risk of dying or requiring hospital readmission for at least 6 months after discharge.
- Conditions
- Malaria, Severe Malaria, Severe Anaemia, Post Discharge
- Trial name
- L9LS-pd (NCT07082205)
- Testing
- Antimalarial monoclonal antibodies, Dihydroartemisinin - Piperaquine (DP)
- Where
- 2 sites in Kenya
- Volunteers
- 398 people
- Sponsor
- Liverpool School of Tropical Medicine
Malaria
A Clinical Study of Piperaquine, Pyronaridine, and Artesunate Administered in Combination in Healthy Adults
This is an open-label pharmacokinetic study in 24 healthy Thai participants. Participants will be admitted in the inpatient ward and each participant will attend a total of 4 visits, including one screening visit and three…
- Trial name
- APP (NCT07470424)
- Testing
- Piperaquine, Artesunate-pyronaridine (Pyramax), Piperaquine and artesunate-pyronaridine (Pyramax)
- Where
- Thailand
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Plasmodium Falciparum Malaria, Malaria
R21/MM Dosing, Presentations, and Preservatives
This is a single blind randomised controlled trial (Phase 3 trial). This study aims to assess whether a half-dose of the R21/Matrix-M malaria vaccine is as effective as the full dose in children and adults.
- Conditions
- Plasmodium Falciparum Malaria, Malaria, Vaccine Reaction
- Trial name
- VAC100 (NCT07194668)
- Testing
- 10μg R21/50μg Matrix-M, 5μg R21/50μg Matrix-M with adaptor preservative free, 5μg R21/50μg Matrix-M with 2PE preservative
- Where
- 2 sites in Bangladesh
- Volunteers
- 375 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Malaria (Plasmodium Falciparum)
Challenge Trial of PfSPZ-LARC2 Vaccine in Burkina Faso
This is a randomized, double-blind, placebo-controlled, Phase 1 trial of Plasmodium falciparum (Pf) late liver stage-arresting replication-competent (LARC) sporozoite (SPZ) malaria vaccine (Sanaria® PfSPZ-LARC2 Vaccine)…
- Trial name
- BFSPZL3 (NCT07730177)
- Testing
- PfSPZ-LARC2 Vaccine, PfSPZ Challenge, Normal Saline
- Where
- Burkina Faso
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Sanaria Inc.
Malaria,Falciparum, Anemia in Children
Preventing Malaria in School Children to Protect the Whole Community in Rural Blantyre District, Malawi
This is an individually randomized, controlled, single blind three arm clinical trial of malaria chemoprevention strategies Arm 1: Intermittent preventive treatment with dihydroartemisinin-piperaquine (IPT-DP).
- Trial name
- NCT06083688
- Testing
- Dihydroartemisinin-Piperaquine, Chloroquine, Sulfadoxine-pyrimethamine-amodiaquine
- Where
- Malawi
- Volunteers
- 788 people, healthy volunteers welcome
- Sponsor
- Liverpool School of Tropical Medicine
Bacteremia
Surveillance of AMR in DRC
This study addresses knowledge gaps regarding antimicrobial resistance (AMR) in sub-Saharan Africa, focusing on evaluating the feasibility of AMR surveillance and enhancing local research capacity.
- Trial name
- SARKIN (NCT06821282)
- Where
- Democratic Republic of the Congo
- Volunteers
- 210 people
- Sponsor
- University of Oxford
Malaria (Plasmodium Falciparum)
PfSPZ-LARC2 Vaccine in Women of Child-bearing Potential (WOCBP) in Mali
A randomized double blind, placebo-controlled study to assess the safety, tolerability, immunogenicity, and protective efficacy of 1, 6, 29-day PfSPZ-LARC2 Vaccine regimen given at a dose of 2 x10^5 PfSPZ or placebo in healthy…
- Trial name
- NCT07675785
- Testing
- PfSPZ-LARC2 Vaccine, Normal Saline
- Where
- Mali
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Sanaria Inc.
Malaria
Integrating the Guardian Spatial Emanator Within AVENIR II
This study will evaluate the implementation of integrating Guardian spatial emanators into the existing AVENIR II azithromycin mass drug administration program in Niger.
- Trial name
- GUARD-AV (NCT07712263)
- Testing
- Spatial Emanator
- Where
- Niger
- Volunteers
- 150,000 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
Malaria, Malaria,Falciparum
A Study to Assess the Safety and Effectiveness of Two Experimental Malaria Vaccines
Malaria is a major public health problem. There were around 240 million cases of malaria and 627,000 deaths worldwide in 2020. There is a great need for a safe, effective malaria vaccine and the team at University of Oxford is…
- Conditions
- Malaria, Malaria,Falciparum, Parasitic Disease, Vector Borne Diseases
- Trial name
- NCT05978037
- Testing
- RH5.1 and/or RH5.2-VLP with Matrix-M
- Where
- United Kingdom
- Volunteers
- 41 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Malaria
Study to Assess Safety and Clinical Responses With Coartem® Baby Dispersible Tablets in Paediatric Patients Weighing 2 to <5 kg With Uncomplicated Malaria
This study is being conducted to further evaluate the safety and clinical outcomes of Coartem® Baby (artemether/lumefantrine 5 mg/60 mg) in neonates and infants weighing ≥2 kg to <5 kg with uncomplicated malaria due to Plasmodium…
- Trial name
- NCT07713602
- Testing
- Coartem® Baby
- Volunteers
- 20 people
- Sponsor
- Novartis Pharmaceuticals
Malaria, Falciparum
A Study to Investigate the Safety of GSK4024484 in Healthy Adult Participants
The primary purpose of the study is to characterise the safety of GSK4024484 in healthy participants within a controlled pharmacokinetic (PK) range, and the effect of food on the study intervention.
- Trial name
- NCT06171113
- Testing
- GSK4024484C
- Where
- United Kingdom
- Volunteers
- 123 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Prevention of Malaria Transmission and Clinical Malaria
Pfs230D1 + R21 in Matrix-M1 in African School Children and Adults
This is a Phase 2, randomized, double-blind, controlled study designed to evaluate the safety, tolerability, immunogenicity, vaccine efficacy, and functional activity of Pfs230D1-CRM197 conjugate vaccine with R21 nanoparticle…
- Trial name
- NCT07147400
- Testing
- 10µg of R21 with 50µg Matrix-M1, 6µg of Pfs230D1-CRM197 + 10µg of R21 with 50µg Matrix-M1 single vial coformulation, RABIVAX-S
- Where
- Mali
- Volunteers
- 1,200 people, healthy volunteers welcome
- Sponsor
- Serum Institute of India Pvt. Ltd.
Malaria, Falciparum
A Phase 2A Study of a Novel Antimalarial Pyrrolidinamide in Adult Patients With Uncomplicated P. Falciparum Malaria
The study will evaluate the safety and efficacy of a new antimalarial drug GSK3772701 (a pyrrolidinamide), using different doses and treatment durations, in adult participants with uncomplicated Plasmodium (P.) falciparum malaria.
- Trial name
- NCT07545681
- Testing
- GSK3772701 600 mg, GSK3772701 900 mg, GSK3772701 150 mg
- Volunteers
- 70 people
- Sponsor
- GlaxoSmithKline
Falciparum; Malaria
The Transmission of Artemisinin Resistant Parasites Before and After Conventional Artemisinin-combination Therapy
A prospective study will be carried out in an area where parasites with reduced sensitivity to malaria drugs (artemisinins) have recently emerged.
- Trial name
- SPARTAN (NCT06347471)
- Testing
- Artemether-lumefantrine, Dihydroartemisinin-Piperaquine
- Where
- 2 sites in Uganda
- Volunteers
- 160 people
- Sponsor
- Infectious Diseases Research Collaboration, Uganda
Malaria (Plasmodium Falciparum)
Safety and Efficacy of Imatinib in Combination With Artemether-Lumefantrine for Uncomplicated Malaria
This study is investigating an innovative approach to treating uncomplicated malaria by adding a drug called Imatinib to the current standard of care, Artemether + Lumefantrine (AL).
- Trial name
- NCT07559370
- Testing
- Artemether lumefantrine tablets, Artemether Lumefantrine and Imatinib Mesylate
- Where
- Kenya
- Volunteers
- 1,116 people
- Sponsor
- Victoria Biomedical Research Institute
Malaria Falciparum
Safety, Tolerability and Efficacy of PfSPZ-LARC2 Vaccine Against CHMI in Malaria-Naïve Adults
This is a randomized, double-blind, placebo-controlled Phase 1 trial of Plasmodium falciparum (Pf) sporozoite (SPZ) late-arresting replication-competent (LARC) malaria vaccine (PfSPZ-LARC2 Vaccine) administered to healthy…
- Trial name
- LARC-Tu (NCT06862453)
- Testing
- PfSPZ-LARC2 Vaccine, PfSPZ Challenge (NF54)
- Where
- Germany
- Volunteers
- 58 people, healthy volunteers welcome
- Sponsor
- Sanaria Inc.
Plasmodium Falciparum Infection
Pharmacokinetic Study of IV Artesunate to Treat Children With Severe Malaria
This clinical study is a phase 4, single-site, open-label pharmacokinetic (PK) study of IV artesunate in up to 100 Ugandan children 6 months-14 years of age who are diagnosed with severe malaria according to standardized World…
- Trial name
- NCT05750459
- Testing
- Artesunate
- Where
- Uganda
- Volunteers
- 90 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Malaria, Falciparum
Single Ascending Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of LAI MMV055 Alone and in Combination With MMV371 in Healthy Participants
This is a single-centre, participant- and investigator-blind, randomised, placebo controlled, single ascending dose study to assess the safety, tolerability and PK of a single dose of IM depot injection(s) of LAI formulations of…
- Trial name
- NCT07011511
- Testing
- MMV055 Dose 1, MMV055 Dose 2, MMV055 Dose 3
- Where
- United Kingdom
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Medicines for Malaria Venture
Malaria
Safety, Tolerability, Pharmacokinetics and Protective Efficacy of MAM01 in Healthy Adults
This is a First-in-Human (FiH), randomized, two-part, dose-escalation trial of MAM01 monoclonal antibody (mAb) targeting the Plasmodium falciparum (Pf) Circumsporozoite Protein (CSP).
- Trial name
- NCT05891236
- Testing
- MAM01 1.5 mg/kg, MAM01 5 mg/kg, MAM01 10 mg/kg
- Where
- United States
- Volunteers
- 63 people, healthy volunteers welcome
- Sponsor
- Gates Medical Research Institute
Malaria
L9LS in Women of Childbearing Potential in Mali
Safety and Efficacy of L9LS, a Human Monoclonal Antibody Against Plasmodium falciparum, in a Randomized, Double-Blind, Placebo-Controlled Trial of Women of Childbearing Potential (WOCBP) in Mali
- Trial name
- NCT07060508
- Testing
- Single dose of 1800 mg L9LS SC
- Where
- 3 sites in Mali
- Volunteers
- 279 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)